Zha et al. Stem Cell Research & Therapy (2018) 9:269
https://doi.org/10.1186/s13287-018-1019-6

Stem Cell Research & Therapy

CORRECTION Open Access

Correction to: PARP1 inhibitor (PJ34) improves the function of aging-induced endothelial progenitor cells by preserving intracellular NAD^+ levels and increasing SIRT1 activity

Siyuan Zha, Zhen Li, Qing Cao, Fei Wang and Fang Liu*

Correction

The original article [1] contains an error regarding the erroneous inclusion of 3 μl as a parameter in the x-axis of Fig. 2c; the correct version of Fig. 2c can instead be seen below.

Received: 3 October 2018 Revised: 3 October 2018
Accepted: 3 October 2018 Published online: 25 October 2018

Reference

1. Zha S, et al. PARP1 inhibitor (PJ34) improves the function of aging-induced endothelial progenitor cells by preserving intracellular NAD^+ levels and increasing SIRT1 activity. Stem Cell Res Ther. 2018;9:224 https://doi.org/10.1186/s13287-018-0961-7.

* Correspondence: liufang@xinhuamed.com.cn
Department of Geriatrics, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China



Fig. 2 Effects of H_2O_2 and PJ34 treatment on EPC protein expression. **a**, **b** Expression of sirtuin 1 (SIRT1), poly (ADP-ribose) polymerase 1 (PARP1), and poly ADP-ribose (PAR) as analyzed by Western blot. **c**, **d** Expression of PARP1, PAR, and acetylated (ac)-p53 as analyzed by Western blot. *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$, versus the control